Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained reduction of...
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new employees under...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Barclays Global Healthcare Conference 2019 - Miami, March 12-14, 2019 March 12, 4:20 p.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018.
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the...
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new February 15th contracts and identified one put and one call contract of particular interest.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV, a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: BIT's 16th Annual Congress of International Drug Discovery Science and Technology - Jinan, China, November 6-8, 2018 November...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc.
Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Jim Cramer says there's still too much greed and complacency, and not enough fear and panic.
Jim Cramer takes a look at AT&T, Arrowhead Research, 3M, HollyFrontier, Brinker International, Viper Energy Partners and more.
Let's see what this biopharma looks like.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company's proprietary Targeted RNAi Molecule (TRiM™) platform.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 9-13, 2018, in San...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: The 14th Annual Meeting of the Oligonucleotide Therapeutics Society - Seattle, September 30-October 3, 2018 October 1, 9:20 a.
